Richard John P, Director, added 1,000 shares of Catalyst Biosciences, Inc. (CBIO) to its portfolio at the rate of $8.03 per share valuing $8,030 on May 24. The insider has now 1,216 shares of the company to its portfolio. Before making a move on any particular stock, readers often pay close attention to support and resistance markers. The last reported price for shares of Catalyst Biosciences, Inc. (CBIO) was $9.31. Currently, the 1st Resistance Point for this stock is $9.99, with a 2nd Resistance Point sitting at $10.66. Meanwhile, this company’s stock has a 1st Support Level at $8.61 and a 2nd Support Level at $7.90. Catalyst Biosciences, Inc. (CBIO) stock has gained $1.64, or 26.32%, in the past five days. In the last full month, these shares have gained $1.69, or 22.18%. In the past three months, this stock’s price has fallen by -$1.29, or -12.17%. This year-to-date, Catalyst Biosciences, Inc. (CBIO) shares have gained $1.42, or 18.00%.
Analyzing price projection indicators is a helpful way to determine whether a potential stock buy is a wise choice for profits in the short term, medium term, and long term. For Catalyst Biosciences, Inc. (CBIO) stock, 60% of short-term indicators suggest that these shares are a “ Buy .” Meanwhile, 50% of medium-term indicators point to this stock being a “ Buy .” Looking further ahead, 33% of long-term indicators suggest that this stock is a “ Buy .”
With 11,980 K shares outstanding, this company currently has a market capitalization of $111,534K. Catalyst Biosciences, Inc. (CBIO) generates $10 K in annual sales, amounting to annual net income of -$30,060 K. This stock has generated a 1-Year Total Return of -18.90%, a 3-Year Total Return of -58.34%, and a 5-year Total Return of -98.00%. This stock’s 5-Year Dividend Growth is 0.00%, with its most recent dividend valued at $0.569 per share on 08/20/15. Its Annual Dividend Yield is 0.00%, and its Annual Dividend Rate is 0.00.
In the most recently-reported fiscal quarter, which ended in Mar-19, Catalyst Biosciences, Inc. (CBIO) reported earnings of -$1.26 per share. Wall Street analysts, on average, were expecting the company to report earnings of -$1.08 per share, representing a -0.18 difference and -17.21% surprise. In the previous quarter ending in Dec-18, the reported earnings of -$0.93 represented a -0.18 difference from the consensus estimate calling for -$0.75 per share, which was a -24.83% surprise.
For the current fiscal quarter, which is set to end in 06/2019, the average earnings estimate is -$1.20 per share. This estimate came from a total of 1 Wall Street Analysts. Of those market experts, the high estimate was -$1.20 and the low estimate was -$1.20. In the year-ago quarter, Catalyst Biosciences, Inc. (CBIO) generated per-share earnings of -$0.54. If the analysts are correct about the current quarter’s earnings, the growth will be -122.22% .
Turning our focus now to insider trading activity, there have been 7 purchases (18,688 shares in total) and 2 sale (20,494 shares in total) in the last 3 months. In the last 6 months, there have been 16 insider buys amounting to 34,842 shares and 2 insider sales amounting to 20,494 shares. In the past full year, 21 insider purchases were made (involving 39,222 shares) and 4 insider sell-offs equivalent to 20,857 shares.
Moving onto liquidity, Catalyst Biosciences, Inc. (CBIO) has a Current Ratio of 25.83, a Quick Ratio of 25.83 and a Cash Ratio of 25.03.